Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study

Author： Kümmel Sherko   Thomas Anke   Paepke Stefan   Schwarz Marion   Heinrich Georg   Wetzel Andrea   Elling Dirk   Kohls Andreas   Lichtenegger Werner   Blohmer Jens-Uwe  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.44, Iss.3, 2005-05, pp. : 248-254

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer

By Cooper Brenda   Radivoyevitch Tomas   Overmoyer Beth   Shenk Robert   Pham Huong   Samuels Judith   Parry Margaret   Silverman Paula  

Breast Cancer Research and Treatment, Vol. 97, Iss. 3, 2006-06 ,pp. : 311-318

Springer Publishing Company

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

By Espinosa E.   Morales S.   Borrega P.   Casas A.   Madroñal C.   Machengs I.   Illarramendi J.   Lizón J.   Moreno J.   Belón J.   Janáriz J.   Puente M.   Checa T.   Mel J.   González Barón M.  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 6, 2004-12 ,pp. : 546-552

Springer Publishing Company

Access to resources Recommend Favorite

Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy

By Lalisang R.   Erdkamp F.   Rodenburg C.   Knibbeler-van Rossum C.   Nortier J.   Bochove A.   Slee P.   Voest E.   Wils J.   Wals J.   Loosveld O.   Smals A.   Blijham G.   Tjan-Heijnen V.   Schouten H.  

Breast Cancer Research and Treatment, Vol. 128, Iss. 2, 2011-07 ,pp. : 437-445

Springer Publishing Company

Access to resources Recommend Favorite

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

By Pierga Jean-Yves   Delaloge Suzette   Espié Marc   Brain Etienne   Sigal-Zafrani Brigitte   Mathieu Marie-Christine   Bertheau Philippe   Guinebretière Jean   Spielmann Marc   Savignoni Alexia   Marty Michel  

Breast Cancer Research and Treatment, Vol. 122, Iss. 2, 2010-07 ,pp. : 429-437

Springer Publishing Company

Access to resources Recommend Favorite